Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
This stock has had more director buys over the last two years than any stock I have ever been involved in. Itās done sweet FA for the SP and will continue to be that way. Brown (Lombard) owns over 15% of the company so wanting him to buy more is ridiculous.
The company keeps delivering. It will continue to do so. In FY26 it will be churning out 10ās of millions in profit, 2 years after that in excess if 100m profit.
If you have done your research you donāt need to want directors to keep buying, and you are delusional if you think it will support the price or otherwise.
Oh you mean this one....
"This contract win is with a leading German Automaker and brings the total OEMs with which Seeing Machines has won business to eight. This program covers an expansive number of vehicle models with mass production scheduled from early 2024 and an initial lifetime value of A$125 million."
"I hope we get an RNS saying something similar!"
Something like this....
"The initial program, already in production, will expand to a total of 19 distinct vehicle models being sold in North America, Europe and China, and extend through 2032 based on the OEM's next generation Driver Monitoring System (DMS) solution utilising Seeing Machines' improved FOVIO Chip design delivering increased feature capability with reduced cost, power and size."
ā Still nothing. It's beginning to look like a patient has dropped out.ā
Not necessarily. Probably a DLT and therefore 3 more patients recruited.
Zero chance of finishing the 2 weekly by mid year as previously stated. Given themselves 6 months from 1st July to start the 1b. My guess be October onwards before that gets going.
At CES 2024 it was stated that Magna are working on Gen2 of the mirror. With Magnaās investment and working relationship with SEE it is highly likely that there will be another exclusive arrangement sign within the next 12-14 months.
There is no chance they complete the next 3 cohorts by end of Juneā¦.. and we want no MTD in the 2 week study. All it takes is one DLT and the timeframe goes out the window so some realism needs to be applied here on the timeframe for the 2 weekly.
As long as the expansion phase starts mid H2 then all is on schedule for P2 early 2025.
**** me you have 19 posts in the last month all moaning like a baby over your own investment decisions and you have one post removed and started two new subjects in one day based on your post getting removed.
get a life and grow up.
The man who is "cutting the fat" has bought significant amounts of shares (nearly 1% of the company) on the open market so he is very much aligned with shareholders to ensure no cash raise.
This company does not have a need to raise any further cash. Within the next 14 months the company reaches cashflow breakeven. Very easy for a CFO of Martin's considerable experience to manage cash, ensuring he is not diluted, in that situation.
The Magna note will be paid in shares, they will own 10% of the company and benefit from the the M&A consolidation of the market which will inevitably occur.
PS. Baxter stop starting a new subject every time you respond to a post....... Anyone cynical like me would think you are trying to push any of the excellent research of Terry and Seize and others down the page so no-one can find it!! The REPLY button is there for a reason!
CTSFO,
See thatās the problem with just using Google for research!
Itās not an error by Avacta at all. It still needs to be recorded as a DLT. You canāt just ignore an event like (cardiac arrest) happened ā¦ā¦ but the whole idea of science is to explain the data and in this case from other information/data on the patients history it was determined by the SDMC that it was unlikely that the drug caused the event. Doesnāt mean itās not recorded as a DLT. The continued study with no further cardiotoxicity showed they were correct.
An abstract is just a summary of data. In a full paper things like this are explained in detail.
Go and watch the science day presentation. The cardiotoxic events were described and was determined to be unrelated to the dosing of ava6000.
The patient who had from the 120mg cohort had grade 1 heart failure during the first cycle of treatment.
the company has told investors for years it had a long list of potential drugs it could potentially licence precision forā¦ā¦ none have eventuated, despite sitting on data since mid to late 2022 that showed the company precision was working.
the company had Ā£60m quid from the cln in october 2022! it got ****ed up the wall on some hairbrained idea to go on a diagnostics buying spree when valuations post covid overvalued the businesses.
there are many ways this latest valuation and fundraise of the company at 50p could have been avoided but management and the board ****ed it up.
there are also plenty of companies that get drugs approved that go onto destroy shareholder value through company mismanagement and commercial inexperience ā¦. stx anyone? getting the leadership right now is essential imo.
as is not ceo calibre for a company with the opportunity to change the landscape of oncology for high fap tumours.
āBut the truth is the business has acquired the necessary resources to reach the key marker of proving the drug and commercialising it.ā
The company doesnāt have anywhere near enough cash to commercialise the drug.
It has enough to get through the P2.
Licence or partnering of ava6000 or the platform are essential in this company driving any value for shareholders.
Extremely unlikely they can recruit quickly enough to complete by end of June in any case considering it has taken from September to basically the end of March to recruit 3 patients.
I donāt believe a new cohort can start without SDMC approving that the previous dosing regime is safe.
They also had 200m in the bank and 3 drugs in the clinic, their own manufacturing plant and have been in partnership with AstraZeneca for 3 yearsā¦ā¦ so there was more to it than just presenting 3 posters at AACR.